Analystreport

Pacific Biosciences of California (NASDAQ: PACB) had its price target lowered by analysts at Piper Sandler from $7.00 to $6.00. They now have an "overweight" rating on the stock.

Pacific Biosciences of California, Inc.  (PACB) 
Last pacific biosciences of california, inc. earnings: 2/6 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.pacificbiosciences.com